Abstract. v-myc avian myelocytomatosis viral oncogene homolog (c-Myc) is an important member protein of the Myc family that is important in cell cycle progression, apoptosis and tumorigenesis. In the present study, the role of c-Myc in rhabdomyosarcoma (RMS) was assessed. Firstly, expression of endogenous c-Myc and cyclin dependent kinase inhibitor 1A (p21) was examined in normal skeletal muscle, RMS specimens and TE671 RMS cells by immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting. Furthermore, cell cycle progression and apoptosis were assessed in TE671 RMS cells following treatment with a c-Myc inhibitor, 10058-F4. The results demonstrated that c-Myc was overexpressed in clinical RMS tissues and TE671 cells, with the highest expression observed in the most RMS samples. Expression of p21 protein and apoptosis function were increased following treatment with 10058-F4, but no difference was observed in cell cycle progression. In conclusion, the present study indicated that c-Myc promotes RMS development by inhibiting apoptosis through repression of p21 transcription. Further studies will be required to evaluate c-Myc as a target for RMS clinical treatment.
Introduction
Rhabdomyosarcoma, commonly referred to as RMS, is an exceedingly rare cancer type. It is categorized as a sarcoma, a cancer of connective tissues, in which the cancer cells are thought to be arise from skeletal muscle progenitors (1, 2) . RMS tumors can occur at any age, but are most common in children under the age of 15 (3, 4) . According to their clinical pathological morphology and genetic variation, RMS tumors can be divided into five subtypes (5, 6) : Botryoid RMS (BRMS), spindle cell RMS (SRMS), embryonal RMS (ERMS), alveolar RMS (ARMS), pleomorphic RMS (PRMS) and undifferentiated sarcoma (7, 8) . RMS tumor prognosis and outcome is highly correlated to these subtypes, suggesting that they exhibit different biological characteristics (9, 10) .
v-myc avian myelocytomatosis viral oncogene homolog (c-Myc) plays an essential role in cell development as a multifunctional effector of cell cycle progression, metabolism, proliferation, apoptosis, cellular transformation and tumorigenesis (11) . A recent study indicated that c-Myc enhances expression of glutamine synthetase (GS), which is responsible for the synthesis of glutamine (Gln) from glutamate (Glu) and ammonia (12) . Gln is a key molecule for nucleotide synthesis, protein synthesis, and the uptake of essential amino acids (EAA) that are required for tumor cell proliferation (12) . Basal expression of cyclin dependent kinase inhibitor 1A (known as p21) in normal and cancer cells contributes to cell population heterogeneity in cell cycle progression and quiescent cell cycle states (13) . High transcription of c-Myc mediates cell transition from G1 to S phase (14) . Chen et al (15) demonstrated that p21 was repressed by c-Myc in hepatocellular carcinoma, via the ERK/c-Myc pathway. However, the role of c-Myc in RMS development remains unknown, and in particular, its relationship with p21.
In the present study, c-Myc protein expression was examined in RMS clinical samples of various subtypes and in the rhabdomyosarcoma cell line TE671. Furthermore, immunohistochemistry, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses were performed in order to explore the mechanism of c-Myc action Immunohistochemistry of c-Myc. Expression of c-Myc in paraffin-embedded RMS tissues was detected using a monoclonal antibody to c-Myc (cat no. ab32072; Abcam, Cambridge, UK), as described previously (16) . Immunostaining was carried out overnight at 4˚C with the c-Myc antibody diluted 1:500, and then incubation with peroxidase complex was performed according to the manufacturer's instructions (catalog no. AR1022; Boster Biological Technology, Pleasanton, CA, USA). Image analysis was performed using a light microscope (Leica Microsystems GmbH, Wetzlar, Germany).
RT-qPCR. Total RNA was extracted using the RNeasy Mini kit (cat no. 74104; Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. Total RNA (1 µg) was used for cDNA synthesis using a First Strand cDNA Synthesis kit (cat no. KR104-01; Tiangen Biotech Co., Ltd., Beijing, China). Gene expression levels were analyzed by qPCR with SYBR Select Master Mix (cat no. 4472908; Thermo Fisher Scientific, Inc.) on a ABI7500 real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Results were normalized to those obtained with human GAPDH primers as an internal reference control and were presented as the fold change in mRNA expression compared with the control group (17) . The apoptosis detection kit was purchased from
Beyotime Institute of Biotechnology (cat no. C1065; Haimen, China). TE671 cells were treated with 60 µM 10058-F4 for 72 h and then harvested by centrifugation at 400 x g for 5 min at room temperature. After washing twice with PBS, 5-10x10 4 cells were resuspended in 195 µl binding buffer, and then stained by adding 5 µl Annexin V-PE for 15 min at room temperature, as per the kit instructions. Finally, the cells were analyzed for presence of apoptotic cells by flow cytometry (BD Biosciences). Each experiment was repeated at least three times.
Protein extraction and western blotting. Cells were lysed in cold immunoprecipitation buffer (60 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.25% SDS and 1% Tergitol-type NP40) containing 10 mM NaF, 1 mM Na 3 VO 4 and complete protease inhibitor (Roche Diagnostics, Basel, Switzerland) for 30 min on ice, and then centrifuged at 10,000 x g at 4˚C. A 1#  M  8  I  ERMS  2#  F  12  II  ERMS  3#  M  8  II  ERMS  4#  M  8  II  ERMS  5#  F  14  I  ERMS  6#  M  11  I  ERMS  7#  F  2  II  ERMS  8#  M  4  II  ERMS  9#  M  23  I  ARMS  10#  M  6  II  ARMS  11#  M  11  III  ARMS  12#  F  22  III  ARMS  13#  M  16  II  ARMS  14#  M  18  II  ARMS  15#  F  14  II  ARMS  16#  F  12  II  ARMS  17#  M  22  II  ARMS  18#  M  21  III  ARMS  19#  F  67  IV  PRMS  20#  F  48  III  PRMS  21#  F  58  III  PRMS  22#  M  63  IV  PRMS  23#  M  49  III  PRMS  24#  F  57  III  PRMS  25#  M  59  II  PRMS  26#  M  48  III  PRMS  27#  F  57  IV  PRMS  28#  M  66  III  PRMS  29#  F  47  III  PRMS  30#  F  52  III 
Results

Overexpression of c-Myc in RMS patient tissue and TE671 cells.
To investigate the role of c-Myc in RMS, the expression level of c-Myc was assessed in RMS tissues and the RMS cell line TE671. ERMS (8 cases), ARMS (10 cases) and PRMS (12 cases) patient tissue samples were collected and processed by immunohistochemistry (IHC) for detection of c-Myc (Table I) . Expression of c-Myc protein was variable in the different tissues (Fig. 1A) . The c-Myc protein was significantly overexpressed in the ERMS, ARMS and PRMS patient tissue compared with the normal skeletal muscle tissues (Fig. 1A) . c-Myc mRNA expression levels were then assessed in RMS samples and TE671 cells (Fig. 1B) . The results demonstrated that c-Myc mRNA was overexpressed in ERMS, ARMS, PRMS and TE671 cells compared with normal control (P<0.01 for ERMS and TE-671 vs. control; P<0.001 for ARMS and PRMS vs. control; Fig. 1B) . These findings therefore suggest that c-Myc may promote the development of RMS. 
c-Myc promotes RMS development by regulating p21 transcription. p21 is an important cell cycle inhibitor protein.
Previous studies have demonstrated that p21 is important in inhibiting cancer cell growth and apoptosis (18, 19) . Therefore, the hypothesis that c-Myc may promote RMS progression by regulating p21 expression was assessed.
Endogenous p21 mRNA expression levels in untreated RMS tissues and TE671 cells were detected (Fig. 2A) . The results demonstrated that normal skeletal muscle tissue, RMS tissue and TE671 cells expressed similar levels of endogenous p21 mRNA, with no significant difference evident among these groups (P>0.05; Fig. 2A ). Following treatment of TE671 cells with 60 µM c-Myc inhibitor 10058-F4 for 24, 48 and 72 h, p21 mRNA expression levels were significantly increased in a time-dependent manner compared with untreated control (P<0.01; Fig. 2B ). In contrast, in the same treatment conditions, c-Myc mRNA expression was significantly decreased in a time-dependent manner (P<0.01 and P<0.001, Fig. 2C ). Expression levels of p21 and c-Myc proteins were also assessed by western blot. p21 protein expression increased as time of treatment increased (Fig. 2D, upper panel) , while c-Myc protein expression was significantly decreased compared with (Fig. 2D, lower panel) . Fig. 2E and F were the relative p21 and c-Myc protein levels respectively, according to Fig. 2C , as determined by densitometric analysis. In conclusion, c-Myc inhibition leads to increased expression of p21, which suggests that c-Myc may promote RMS development by repressing p21 transcription.
Effect of c-Myc inhibition on RMS cell apoptosis. TE671 cells
were treated with 60 µM 10058-F4 for 72 h, following which, apoptosis was measured by Annexin V-PE staining. As demonstrated in Fig. 3 the apoptosis rate of untreated cells (red line) was significantly lower than the inhibitor-treated cells (blue line). The result indicated that c-Myc inhibition leads to reduction of apoptosis in TE671 cells, thus suggesting that c-Myc plays an important role in maintaining RMS cell viability.
Effect of c-Myc inhibion on cell cycle.
In the present study, c-Myc was demonstrated to downregulate p21. Due to the function of p21 as a critical cell cycle kinase inhibitor, the role of c-Myc inhibition in TE671 cell cycle progression was assessed by flow cytometry (Fig. 4) . No difference in the cell cycle analysis of untreated (Fig. 4A) vs. 10058-F4-treated cells (Fig. 4B) was evident. The result demonstrated that inhibition of c-Myc did not affect phase transition in TE671 cells, suggesting that c-Myc does not play a role in cell cycle regulation in RMS cells (Table II) .
Discussion
Recently, new discoveries and molecular mechanisms about RMS development have emerged in large numbers. RMS has been linked to altered levels of several proliferation-related cytokines and cell signaling pathways (20, 21) , and chromosomal abnormalities, such as PAX3-FKHR and PAX7-FKHR gene fusions, and heterozygous or homozygous gene deletions (8) . Abnormal expression of specific genes, for example 11p15.5, is capable of promoting proliferation of RMS cells (9) . In addition, a previous study has indicated that the proliferation markers PCNA and Ki-67 are overexpressed in RMS cells, suggesting that RMS cells have a high proliferation activity (22) . In the present study, c-Myc expression was assessed in clinical RMS samples and TE671 RMS cells. In addition, the role of c-Myc in the regulation of p21 was examined.
c-Myc is localized to the cell nucleus, where transcription is not easily affected by external environmental factors. c-Myc, as a proliferation-promoting oncogene, interacts with other transcription factors to regulate the transcription of various genes (23) . In the present study, c-Myc was discovered to be overexpressed in TE671 cells and in clinical RMS tissues. In addition, levels of c-Myc protein and mRNA expression were associated with malignancy of RMS (24, 25) . Previous studies have demonstrated that expression of c-Myc in normal skeletal muscle and reactive hyperplasia tissues and lymphocytes of RMS exists in order to maintain normal physiological function (12) . The c-Myc inhibitor 10058-F4 is a small molecule compound that penetrates through the cell membrane and the nuclear membrane (13) . The inhibitor specifically blocks the binding region of the c-Myc leucine zipper domain and results in c-Myc not recognizing the CACGTG motif sequence, thus inhibiting transcription of target genes (15) . In the present study, p21 expression was demonstrated to be significantly increased following c-Myc inhibition in RMS cells. Due to the importance of p21 in cell apoptosis and the cell cycle, the effect of c-Myc inhibition on RMS cell behavior was further assessed. Apoptosis was significantly increased following 10058-F4 treatment, while cell cycle was not affected (Figs. 3  and 4, respectively) . p21 belongs to the cyclin-dependent kinase interacting protein/Kinase inhibitory protein family (26) , and, together with tumor protein p53, contributes to the cell cycle G1 checkpoint (27) . In the present study, no effect on cell cycle was observed following c-Myc inhibition, which suggests that synergistic action with another signaling pathway may be required for its role on cell proliferation. c-Myc is an oncogene and p21 is a tumor suppressor gene (28) . In the present study, c-Myc was demonstrated to promote RMS development by repressing p21 transcription. Further studies on the functions of c-Myc and p21 in RMS cells would greatly benefit future RMS research and therapy development.
